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Over the past few years Dr. Quinn and his lab have made significant progress 
in the development of a melanoma treatment drug. Based upon peptide analogs 
of the alpha-melanocyte stimulating hormone, Α-MSH, Dr. Quinn has developed a 
metal cyclized drug that shows very promising results in therapy as well as 
early detection/imaging of melanoma tumors. The cyclization of the peptide 
around a metal core was shown to greatly increase the affinity of the peptide 
for its target. There are slight problems with the cyclization process that 
needed to be resolved or limited in order to make the synthesis of the drug 
as efficient as possible. The primary problem with the cyclization of the 
peptide is the fact that two main products are produced. One of these 
products is caused by the histidine residue swinging down and binding with 
the metal core. Histidine is one of the four amino acids directly involved 
with receptor recognition and thus this product’s tumor uptake is at least 
50% lower.  
 
Three variables were explored in hopes of reducing this second unwanted 
product. A new and simpler process developed by Fridkin et. al. ¹ was first 
considered. HPLC was used to purify the two major products and their 
identities were confirmed using mass spectrometry. The new procedure proved 
to be slightly more effective as the old procedure. With the old procedure 
roughly 32.3% of the two major products were of the undesired compound, 
however, using this new procedure this was reduced to 23.4%. A variation of 
the new procedure was then tried. Instead of dissolving the linear peptide in 
water, as the procedure called to do, the peptide was dissolved using DMF. 
This modification showed a significant change in the percentage of the two 
products. Of the two major products only 12.8% of the total was of the 
unwanted product thus producing 87.2% of the desired cyclized peptide. 
Finally an addition of an extra amino acid residue near the beginning of the 
sequence was tried in hopes of moving the histidine residue far enough away 
from the metal core in order to limit their interaction. Current tests are 
still being performed to determine whether or not this will be successful.  
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